Skip to contentC
CNBX Pharmaceuticals Inc.
C
CNBXCNBX Pharmaceuticals Inc. Q4 2019 · 10-K
derived · Computed from the longer spans the company filed.
Revenue$2.06K$2.06Kderivedno prior Q4 2018 on file Net Income-$1.39M-$1.39Mderivedno prior Q4 2018 on file EPS, diluted—
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
CNBX Pharmaceuticals Inc. · CIK 1343009 · Engraved from SEC EDGAR
Not derived. Share counts vary by quarter.
Operating Incomederived-$979,748— Operating Cash Flowderived-$868,673— Margins · derivedOperating margin-47606.8%
Net margin-67700.3%
ended Aug 31, 2019 · filed Nov 29, 2019 · 90 d after period end